Hui Xian Poh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hui Xian Poh has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
Samie R. Jaffrey
12 shared publicationsBriana C. Prager
11 shared publications- Jing Crystal Zhao
Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA
11 shared publications - Kristoffer Vitting-Seerup
Section for Bioinformatics, Department of Health Technology, The Technical University of Denmark, Kgs. Lyngby, Denmark
11 shared publications - Leo Jin Young Kim
Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, CA 92037, USA
11 shared publications Li Jiang
11 shared publications
Latest Publications
- Open Access
FTO does not function as an m 6 A eraser in AML: a reassessment using direct RNA nanopore sequencing
SUMMARY: A central concept in epitranscriptomics is that the RNA demethylase FTO acts as a site-selective eraser of N 6 -methyladenosine (m 6 A) in specific mRNAs. This is most well-established in acute myeloid leukemia (AML), where demethylation of MYC is thought to promote leukemogenesis. Using nanopore direct RNA sequencing to quantify m 6 A transcriptome-wide, we find that m 6 A stoichiometry, including at MYC -specific sites, remains unaffected by FTO knockdown or pharmacologic inhibition in AML. Conversely, levels of N 6 -2’-O-dimethyladenosine (m 6 Am) are markedly increased in snRNAs, indicating that m 6 Am, not m 6 A, is the major substrate of FTO in AML. We extend these results outside the AML context in FTO knockout brain and HEK293T cells, detecting no selective increases in mRNA m 6 A but widespread increases in snRNA m 6 Am levels following FTO depletion. These findings suggest that FTO has minimal ability to erase m 6 A in mRNA. Instead, the reported biological effects of FTO are likely mediated by demethylation of m 6 Am.
Open AccessFTO does not function as an m 6 A eraser in AML: a reassessment using direct RNA nanopore sequencing
SUMMARY: A central concept in epitranscriptomics is that the RNA demethylase FTO acts as a site-selective eraser of N 6 -methyladenosine (m 6 A) in specific mRNAs. This is most well-established in acute myeloid leukemia (AML), where demethylation of MYC is thought to promote leukemogenesis. Using nanopore direct RNA sequencing to quantify m 6 A transcriptome-wide, we find that m 6 A stoichiometry, including at MYC -specific sites, remains unaffected by FTO knockdown or pharmacologic inhibition in AML. Conversely, levels of N 6 -2’-O-dimethyladenosine (m 6 Am) are markedly increased in snRNAs, indicating that m 6 Am, not m 6 A, is the major substrate of FTO in AML. We extend these results outside the AML context in FTO knockout brain and HEK293T cells, detecting no selective increases in mRNA m 6 A but widespread increases in snRNA m 6 Am levels following FTO depletion. These findings suggest that FTO has minimal ability to erase m 6 A in mRNA. Instead, the reported biological effects of FTO are likely mediated by demethylation of m 6 Am.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells
Glioblastoma is a universally lethal cancer driven by glioblastoma stem cells (GSC). Here, we interrogated N6-methyladenosine (m6A) mRNA modifications in GSCs by methyl RNA immunoprecipitation followed by sequencing and transcriptome analysis, finding transcripts marked by m6A often upregulated compared with normal neural stem cells (NSC). Interrogating m6A regulators, GSCs displayed preferential expression, as well as in vitro and in vivo dependency, of the m6A reader YTHDF2, in contrast to NSCs. Although YTHDF2 has been reported to destabilize mRNAs, YTHDF2 stabilized MYC and VEGFA transcripts in GSCs in an m6A-dependent manner. We identified IGFBP3 as a downstream effector of the YTHDF2–MYC axis in GSCs. The IGF1/IGF1R inhibitor linsitinib preferentially targeted YTHDF2-expressing cells, inhibiting GSC viability without affecting NSCs and impairing in vivo glioblastoma growth. Thus, YTHDF2 links RNA epitranscriptomic modifications and GSC growth, laying the foundation for the YTHDF2–MYC–IGFBP3 axis as a specific and novel therapeutic target in glioblastoma.Significance:Epitranscriptomics promotes cellular heterogeneity in cancer. RNA m6A landscapes of cancer and NSCs identified cell type–specific dependencies and therapeutic vulnerabilities. The m6A reader YTHDF2 stabilized MYC mRNA specifically in cancer stem cells. Given the challenge of targeting MYC, YTHDF2 presents a therapeutic target to perturb MYC signaling in glioblastoma.This article is highlighted in the In This Issue feature, p. 211
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells
Glioblastoma is a universally lethal cancer driven by glioblastoma stem cells (GSC). Here, we interrogated N6-methyladenosine (m6A) mRNA modifications in GSCs by methyl RNA immunoprecipitation followed by sequencing and transcriptome analysis, finding transcripts marked by m6A often upregulated compared with normal neural stem cells (NSC). Interrogating m6A regulators, GSCs displayed preferential expression, as well as in vitro and in vivo dependency, of the m6A reader YTHDF2, in contrast to NSCs. Although YTHDF2 has been reported to destabilize mRNAs, YTHDF2 stabilized MYC and VEGFA transcripts in GSCs in an m6A-dependent manner. We identified IGFBP3 as a downstream effector of the YTHDF2–MYC axis in GSCs. The IGF1/IGF1R inhibitor linsitinib preferentially targeted YTHDF2-expressing cells, inhibiting GSC viability without affecting NSCs and impairing in vivo glioblastoma growth. Thus, YTHDF2 links RNA epitranscriptomic modifications and GSC growth, laying the foundation for the YTHDF2–MYC–IGFBP3 axis as a specific and novel therapeutic target in glioblastoma.Significance:Epitranscriptomics promotes cellular heterogeneity in cancer. RNA m6A landscapes of cancer and NSCs identified cell type–specific dependencies and therapeutic vulnerabilities. The m6A reader YTHDF2 stabilized MYC mRNA specifically in cancer stem cells. Given the challenge of targeting MYC, YTHDF2 presents a therapeutic target to perturb MYC signaling in glioblastoma.This article is highlighted in the In This Issue feature, p. 211
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells
Supplementary figures and legends
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells
Supplementary figures and legends
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells
Glioblastoma is a universally lethal cancer driven by glioblastoma stem cells (GSC). Here, we interrogated N6-methyladenosine (m6A) mRNA modifications in GSCs by methyl RNA immunoprecipitation followed by sequencing and transcriptome analysis, finding transcripts marked by m6A often upregulated compared with normal neural stem cells (NSC). Interrogating m6A regulators, GSCs displayed preferential expression, as well as in vitro and in vivo dependency, of the m6A reader YTHDF2, in contrast to NSCs. Although YTHDF2 has been reported to destabilize mRNAs, YTHDF2 stabilized MYC and VEGFA transcripts in GSCs in an m6A-dependent manner. We identified IGFBP3 as a downstream effector of the YTHDF2–MYC axis in GSCs. The IGF1/IGF1R inhibitor linsitinib preferentially targeted YTHDF2-expressing cells, inhibiting GSC viability without affecting NSCs and impairing in vivo glioblastoma growth. Thus, YTHDF2 links RNA epitranscriptomic modifications and GSC growth, laying the foundation for the YTHDF2–MYC–IGFBP3 axis as a specific and novel therapeutic target in glioblastoma.Significance:Epitranscriptomics promotes cellular heterogeneity in cancer. RNA m6A landscapes of cancer and NSCs identified cell type–specific dependencies and therapeutic vulnerabilities. The m6A reader YTHDF2 stabilized MYC mRNA specifically in cancer stem cells. Given the challenge of targeting MYC, YTHDF2 presents a therapeutic target to perturb MYC signaling in glioblastoma.This article is highlighted in the In This Issue feature, p. 211
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells
Glioblastoma is a universally lethal cancer driven by glioblastoma stem cells (GSC). Here, we interrogated N6-methyladenosine (m6A) mRNA modifications in GSCs by methyl RNA immunoprecipitation followed by sequencing and transcriptome analysis, finding transcripts marked by m6A often upregulated compared with normal neural stem cells (NSC). Interrogating m6A regulators, GSCs displayed preferential expression, as well as in vitro and in vivo dependency, of the m6A reader YTHDF2, in contrast to NSCs. Although YTHDF2 has been reported to destabilize mRNAs, YTHDF2 stabilized MYC and VEGFA transcripts in GSCs in an m6A-dependent manner. We identified IGFBP3 as a downstream effector of the YTHDF2–MYC axis in GSCs. The IGF1/IGF1R inhibitor linsitinib preferentially targeted YTHDF2-expressing cells, inhibiting GSC viability without affecting NSCs and impairing in vivo glioblastoma growth. Thus, YTHDF2 links RNA epitranscriptomic modifications and GSC growth, laying the foundation for the YTHDF2–MYC–IGFBP3 axis as a specific and novel therapeutic target in glioblastoma.Significance:Epitranscriptomics promotes cellular heterogeneity in cancer. RNA m6A landscapes of cancer and NSCs identified cell type–specific dependencies and therapeutic vulnerabilities. The m6A reader YTHDF2 stabilized MYC mRNA specifically in cancer stem cells. Given the challenge of targeting MYC, YTHDF2 presents a therapeutic target to perturb MYC signaling in glioblastoma.This article is highlighted in the In This Issue feature, p. 211